Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

<p>Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) Objective response rat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autore principale: Biagio Ricciuti (14951247) (author)
Altri autori: Arielle Elkrief (15055750) (author), Joao Alessi (15561455) (author), Xinan Wang (15561458) (author), Yvonne Li (15561461) (author), Hersh Gupta (15561464) (author), Daniel M. Muldoon (15561467) (author), Arrien A. Bertram (14954848) (author), Federica Pecci (15561470) (author), Giuseppe Lamberti (15024714) (author), Alessandro Di Federico (15561473) (author), Adriana Barrichello (15561476) (author), Victor R. Vaz (15561479) (author), Malini Gandhi (15561482) (author), Elinton Lee (15561485) (author), Geoffrey I. Shapiro (14961801) (author), Hyesun Park (15561488) (author), Mizuki Nishino (15561491) (author), James Lindsay (15032271) (author), Kristen D. Felt (15561494) (author), Bijaya Sharma (15561497) (author), Andrew D. Cherniack (14959412) (author), Scott Rodig (15561500) (author), Daniel R. Gomez (15561503) (author), Narek Shaverdian (15561506) (author), Mehrdad Rakaee (15561509) (author), Chaitanya Bandlamudi (15047205) (author), Marc Ladanyi (15050661) (author), Pasi A. Janne (15561512) (author), Adam J. Schoenfeld (15022025) (author), Lynette M. Sholl (15032729) (author), Mark M. Awad (14961722) (author), Michael L. Cheng (15561515) (author)
Pubblicazione: 2025
Soggetti:
Cancer
Molecular and Cellular Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Biomarkers
Genetic biomarkers
DNA Damage and Repair
DNA repair
Lung Cancer
Precision Medicine
Translational Research
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Descrizione
Riassunto:<p>Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 intermediate (1-49%) NSCLC, according to ATM mutation status. (G) Objective response rate, (H) progression-free survival, and (I) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 high (≥50%) NSCLC, according to ATM mutation status.</p>

Documenti analoghi